Equities Analysts Issue Forecasts for EWTX Q1 Earnings

Edgewise Therapeutics, Inc. (NASDAQ:EWTX) – Equities research analysts at HC Wainwright issued their Q1 2026 earnings per share (EPS) estimates for Edgewise Therapeutics in a research report issued to clients and investors on Thursday, February 26th. HC Wainwright analyst J. Pantginis forecasts that the company will earn ($0.43) per share for the quarter. The consensus estimate for Edgewise Therapeutics’ current full-year earnings is ($1.45) per share. HC Wainwright also issued estimates for Edgewise Therapeutics’ Q2 2026 earnings at ($0.47) EPS, Q3 2026 earnings at ($0.51) EPS and Q4 2026 earnings at ($0.60) EPS.

Edgewise Therapeutics (NASDAQ:EWTX) last announced its quarterly earnings data on Thursday, February 26th. The company reported ($0.47) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.04).

Several other brokerages have also recently weighed in on EWTX. Weiss Ratings reissued a “sell (d-)” rating on shares of Edgewise Therapeutics in a research report on Wednesday, January 21st. Royal Bank Of Canada lifted their target price on shares of Edgewise Therapeutics from $49.00 to $50.00 and gave the stock an “outperform” rating in a research note on Friday, November 7th. JPMorgan Chase & Co. boosted their target price on shares of Edgewise Therapeutics from $33.00 to $34.00 and gave the company an “overweight” rating in a report on Friday, November 14th. Wedbush cut their price target on shares of Edgewise Therapeutics from $35.00 to $32.00 and set an “outperform” rating for the company in a report on Friday, November 7th. Finally, Stifel Nicolaus set a $25.00 price target on shares of Edgewise Therapeutics in a research report on Thursday. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Edgewise Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $36.36.

Edgewise Therapeutics Stock Up 2.6%

Shares of NASDAQ:EWTX opened at $30.44 on Friday. Edgewise Therapeutics has a 52-week low of $10.60 and a 52-week high of $31.82. The stock has a market cap of $3.22 billion, a P/E ratio of -18.67 and a beta of 0.27. The business has a fifty day moving average of $27.62 and a two-hundred day moving average of $21.17.

Insider Buying and Selling

In other news, Director Badreddin Edris sold 115,471 shares of the firm’s stock in a transaction on Wednesday, January 21st. The stock was sold at an average price of $29.44, for a total transaction of $3,399,466.24. Following the completion of the transaction, the director directly owned 19,820 shares in the company, valued at $583,500.80. This trade represents a 85.35% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 23.20% of the stock is owned by company insiders.

Hedge Funds Weigh In On Edgewise Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Optimize Financial Inc grew its position in Edgewise Therapeutics by 1.5% in the 4th quarter. Optimize Financial Inc now owns 27,679 shares of the company’s stock valued at $687,000 after acquiring an additional 396 shares in the last quarter. Steward Partners Investment Advisory LLC boosted its stake in shares of Edgewise Therapeutics by 23.9% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 2,854 shares of the company’s stock valued at $71,000 after purchasing an additional 550 shares during the period. California State Teachers Retirement System grew its holdings in shares of Edgewise Therapeutics by 2.4% in the second quarter. California State Teachers Retirement System now owns 36,878 shares of the company’s stock valued at $483,000 after purchasing an additional 850 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Edgewise Therapeutics by 26.3% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,145 shares of the company’s stock valued at $128,000 after purchasing an additional 1,072 shares in the last quarter. Finally, HighMark Wealth Management LLC increased its stake in Edgewise Therapeutics by 2.1% during the 3rd quarter. HighMark Wealth Management LLC now owns 53,179 shares of the company’s stock worth $863,000 after buying an additional 1,114 shares during the period.

Key Edgewise Therapeutics News

Here are the key news stories impacting Edgewise Therapeutics this week:

• Positive Sentiment: Multiple near‑term clinical catalysts could drive upside: management flagged CIRRUS‑HCM 12‑week data for EDG‑7500 and Phase 1 healthy‑adult data for EDG‑15400 (with planned heart‑failure studies) expected in H1 2026, and pivotal GRAND CANYON results for sevasemten in Becker muscular dystrophy anticipated in Q4 2026. These readouts materially de‑risk the pipeline and are likely the main reason investors are buying the stock. PR Newswire: Q4 & Full Year 2025 Results
• Positive Sentiment: Company increased R&D investment in Q4, signaling management is funding those near‑term trials and pivotal work — a positive for long‑term value creation if the upcoming readouts are favorable. BizWest: R&D boost
• Neutral Sentiment: Analyst modeling: HC Wainwright published quarterly EPS forecasts for 2026 (Q1 -$0.43, Q2 -$0.47, Q3 -$0.51, Q4 -$0.60; full‑year -$1.45). These estimates reinforce expectations of continued operating losses as the company advances trials; they provide a near‑term earnings framework but don’t change the pipeline narrative. MarketBeat: HC Wainwright estimates
• Neutral Sentiment: Valuation discussion: recent coverage (e.g., Yahoo Finance) examines EWTX’s strong multi‑year returns and recent momentum, useful for investors assessing whether current share price already reflects upcoming catalysts. Yahoo Finance: Valuation piece
• Negative Sentiment: Q4 earnings miss and near‑term financial drag: Edgewise reported EPS of ($0.47) for the quarter, missing the consensus ($0.43). The combination of the miss and higher R&D spend increases short‑term risk and means more funding will likely be required before positive cash flow. Press Release: Q4 Results

Edgewise Therapeutics Company Profile

Edgewise Therapeutics, Inc (NASDAQ: EWTX) is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts, focused on the discovery and development of precision medicines for the treatment of rare diseases. The company leverages its expertise in small-molecule chemistry and ion channel biology to address severe, unmet medical needs, particularly in the areas of kidney disorders and neuromuscular diseases.

At the core of Edgewise’s pipeline is EWTX-101, a novel, orally available inhibitor of TRPC5, a calcium channel implicated in nephrotic syndromes such as focal segmental glomerulosclerosis (FSGS) and other proteinuric kidney diseases.